ABSTRACT. Hypercholesterolemia is one of the major contributing factors in atherosclerosis and the development of cardiovascular disease. Platelets from hypercholesterolemic rabbit have an increased cholesterol content and a hypersensitivity to endogenous aggregating agonists. Although rabbit has been widely used in studies of hypercholesterolemia, the precise role of platelet cholesterol in rabbit platelet activation has not been studied. In the present study, to determine the direct role of cholesterol on rabbit platelet activation, we examined the effect of in vitro modulation of cholesterol content on platelet activation. Cholesterol-depleted rabbit platelets by the treatment with methyl--cyclodextrin showed decreased platelet aggregation by physiological agonists such as thrombin, adenosine diphosphate, and collagen. The inhibition of thrombin-induced aggregation in cholesterol-depleted platelets was restored by cholesterol repletion in platelets. The cholesterol depletion also inhibited Ca 2+ mobilization, which plays a pivotal role in the platelet activation induced by physiological agonists. We showed that the Ca 2+ influx pathway is strongly suppressed by cholesterol depletion more than Ca 2+ release from intracellular Ca 2+ stores in platelets stimulated with thrombin. Furthermore, platelet aggregation induced by PMA, a potent protein kinase C activator, was also depressed by cholesterol depletion. On the other hand, cholesterol enrichment in platelets augmented thrombininduced aggregation and Ca 2+ mobilization. These findings suggest that cholesterol plays a critical role in regulating rabbit platelet activation, and provides fundamental information regarding hypercholesterolemia-mediated effects on cells in the rabbit model.
Platelets play an essential role in hemostasis. At sites of vascular injury, circulating platelets adhere to exposed subendothelial collagen with the aid of von Willebrand factor and become activated. Activated platelets undergo shape change and spreading; they also release factors such as adenosine diphosphate (ADP) and thromboxane A 2 (TXA 2 ) that activate additional platelets. In contrast, thrombin is generated during blood coagulation and acts as a potent platelet activator. Activated platelets result in platelet aggregation to form a haemostatic plug at the injury site. It has become increasingly evident that platelets not only play an important role in hemostasis but also are involved in pathological conditions such as thrombosis and atherosclerosis [15, 33] .
Hypercholesterolemia is one of the major contributing factors in atherosclerosis and the development of cardiovascular disease [14, 29] . Platelets from hypercholesterolemic humans have increased cholesterol content and hypersensitivity to endogenous aggregating agonists [9, 21, 25] . In familial hypercholesterolemic patients, cholesterol-lowering treatment with statin, an HMG-CoA reductase inhibitor, decreases the platelet cholesterol content and platelet sensitivity to the aggregating agonists such as ADP and collagen [9, 17, 18] . On the other hand, in vitro cholesterol depletion from the human platelet membrane decreases platelet sensitivity to the agonists such as ADP, collagen, and thrombin, and reduces the release of TXA 2 and ADP [1, 7, 20, 30] . In contrast, in vitro cholesterol enrichment of human platelets results in hypersensitivity to agonists [13, 26] . These previous studies have indicated that the cholesterol content directly influences human platelet activation, and suggest an important role for hypersensitive platelets in the development of thrombosis and atherosclerosis.
The rabbit has been widely used in studies of atherosclerosis because, in addition to its size and easy manipulation, mild cholesterol supplementation in the rabbit leads to hypercholesterolemia and subsequent atherosclerosis [12, 23, 35] . Furthermore, a spontaneously hypercholesterolemic model, Watanabe heritable hyperlipidemic rabbits (WHHL) [34] , is available and has been utilized to understand human familiar hypercholesterolemia and atherosclerosis. Although an increased cholesterol content and hypersensitivity of platelets from hypercholesterolemic rabbit has been reported [3, 28] , the precise role of platelet cholesterol in rabbit platelet activation has not been studied. In the present study, to determine the direct role of cholesterol in rabbit platelet activation, we examined the effects of in vitro modulation of cholesterol content on platelet aggregation and Ca 2+ mobilization induced by physiological agonists such as thrombin, collagen, or ADP.
MATERIALS AND METHODS

Materials:
Methyl--cyclodextrin (MCD), cholesterol, ADP, thrombin, phorbol 12-myristate 13-acetate (PMA), apyrase, and bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO, U.S.A). Collagen was from Nycomed Pharma (Oslo, Norway). Prostaglandin E 1 (PGE 1 ) was purchased from Cayman Chemical (Ann Arbor, MI, U.S.A.). Fura-PE3/AM was purchased from Teflabs (Austin, TX, U.S.A.). Aspirin and the cholesterol kit (cholesterol E-test wako) were from Wako Pure Chem (Osaka, Japan). Protein assay CBB solution was from Nacalai tesque (Kyoto, Japan).
Platelet preparation: Blood was obtained from the marginal ear vein of male Japanese white rabbit (2.5-3.5 kg), and was mixed with a one-tenth volume of 3.8% sodium citrate as anticoagulant. Platelet-rich plasma (PRP) was prepared by centrifugation of blood at 160 g for 10 min at room temperature. The PRP was centrifuged at 670 g for 10 min in the presence of 1 M PGE 1 and 0.05 unit/ml apyrase to prevent platelet activation during the centrifugation. The pelleted platelets were resuspended with Hepes-Tyrode's buffer (20 mM Hepes, 0.34 mM NaH 2 PO 4 , 137 mM NaCl, 1 mM MgCl, 2.7 mM KCl, 12 mM NaHCO 3 , 5.5 mM glucose, pH 6.35), and the platelets were then pelleted again in the presence of PGE 1 and apyrase. The platelets were resuspended, and the count was adjusted to 3  10 8 platelets/ml with Hepes-Tyrode's buffer (pH 7.4) containing 0.35% BSA.
Modulation of platelet cholesterol: Cholesterol depletion was performed by incubation of PRP with 5 mM MCD, which is commonly used to remove cholesterol from cell plasma membranes [36] , for 15 min at 37C. In contrast, the cholesterol content in platelets was enriched by incubation of PRP with 0.2 mM cholesterol complexed with 2 mM MCD, which was prepared as described by Furuchi and Anderson [6] . In the cholesterol/MCD complexs, MCD acts as carriers for cholesterol and donate cholesterol to the platelet membrane. For cholesterol repletion, cholesteroldepleted (MCD-treated) platelets were centrifuged and resuspended in Hepes-Tyrode's buffer (pH 6.35) containing 0.5 mM cholesterol (complexed with MCD), and then incubated for 30 min at 37C. These platelets were washed as described above and used for the aggregation experiment and measurement of Ca 2+ mobilization. Measurement of platelet aggregation: Agonist-induced platelet shape change and aggregation was analyzed in the presence of 1 mM CaCl 2 , unless otherwise indicated, by measuring light transmission through the platelet suspension using a HEMA TRACER (Niko Bioscience Co, Tokyo, Japan) or a CAF-100 (JASCO, Tokyo, Japan) at 37C with constant stirring. For each experiment, the aggregometer was calibrated with Hepes-Tyrode's buffer (pH 7.4) for 100% transmission and with a platelet supension for 0% transmission. The extent of the aggregation is expressed as a percentage of transmission. Shape change is indicated as a decrease in light transmission through the suspension. It should be noted that the shape change is presented graphically in this paper as a downward deflection in the traces.
Measurement of intracellular Ca
2+
mobilization: Platelets in Hepes-Tyrode's buffer (pH 6.35) were incubated with 2 M fura-PE3/AM, a fluorescent calcium indicator, for 30 min at 37C. Platelets were then washed and resuspended as described above. Changes in fluorescence were measured using a CAF-100 (JASCO, Tokyo, Japan) at 37C with constant stirring at excitation wavelengths of 340 and 380 nm and at an emission wavelength of 500 nm. Fluorescence measurements were converted to Ca 2+ concentrations using the equation reported by Grynkiewicz et al. [8] with a K D value of 290 nM for fura-PE3 [32] . F min and F max were determined with each respective platelet preparation.
Protein and cholesterol assay: Protein concentrations were determined using the Bradford method. Platelet cholesterol content was determined with a cholesterol assay kit following the extraction of platelet lipids from the platelet suspension by the method of Folch et al. [5] .
Statistical analysis: The results are expressed as the means  SEM. The differences between means were evaluated by Student's t-test or one-way ANOVA followed by Tukey's test for multiple comparisons, and were considered significant at P<0.05.
RESULTS
Effects of cholesterol depletion on thrombin-induced platelet aggregation:
We first examined the effects of membrane cholesterol depletion by treatment of rabbit platelets with 5 mM MCD, which removed cholesterol from the plasma membranes, on platelet shape change and aggregation induced by thrombin in the presence of 1 mM CaCl 2 . Stimulation of platelets with thrombin (0.01-1 unit/ml) elicited rapid shape change followed by aggregation response in a dose-dependent manner (Fig. 1 ). The platelet shape change (downward change in trace) induced by thrombin did not differ between MCD-treated and untreated platelets (Fig. 1A) . When platelets were stimulated with the submaximal concentration (0.1 unit/ml) of thrombin, MCD-treated platelets showed a significant decrease in the aggregation response in comparison with the control platelets (55.7  8.0% in control and 22.5  11.1% in MCD-treated platelets, P<0.05, n=5). However, the extent of platelet aggregation induced by the higher concentration of thrombin (1 unit/ml) was not significantly different between MCD-treated and control platelets (Fig. 1B) .
To confirm that the inhibitory effect of MCD on platelet aggregation is due to the depletion of cholesterol in platelets, we examined the effects of cholesterol depletion/repletion on cholesterol content and thrombin-induced aggregation (Fig. 2) . In MCD-treated platelets, the cholesterol content was significantly decreased in comparison with control platelets (0.47  0.07 mg in control and 0.20  0.03 mg in MCD-treated platelets, P<0.05, n=5, in Fig.  2A ), in coincidence with the inhibition of aggregation induced by thrombin (Fig. 2B) . When MCD-treated platelets were incubated with cholesterol/MCD complex to replete platelet cholesterol, the cholesterol content and thrombin-induced aggregation were recovered to control values. These results suggested that the inhibition of platelet aggregation by treatment with MCD was due to the depletion of cholesterol in platelets. ] i ) is an essential step in platelet activation induced by most agonists [22] , we studied the effects of cholesterol depletion on [Ca 2+ ] i in fura-PE3-loaded rabbit platelets. We first observed the effects of cholesterol depletion on thrombin-induced Ca 2+ mobilization in the presence of 1 mM CaCl 2 (Fig. 3) . In control platelets, stimulation with thrombin (0.01-1 unit/ml) elicited an increase in [Ca 2+ ] i in a dose-dependent manner (Fig.  3B) . The increase in [Ca 2+ ] i induced by 0.01-1 unit/ml thrombin was diminished in MCD-treated platelets in comparison with that in control platelets, although the inhibition was most apparent at lower concentrations of thrombin.
Effects of cholesterol depletion on thrombin-induced Ca
Increases influx induced by thrombin (Fig. 4) . To observe Ca 2+ release from Ca 2+ stores, fura-PE3-loaded platelets were stimulated by thrombin for 3 min in the absence of extracellular Ca 2+ (with 1 mM EGTA added), and then 2 mM CaCl 2 was added to the extracellular buffer to elicit Ca 2+ influx (Fig. 4A) . Although cholesterol depletion tends to reduce Ca 2+ release from intracellular stores 5A ). In agreement with the results for platelet aggregation, we observed that Ca 2+ mobilization induced by ADP or collagen was inhibited in cholesterol-depleted platelets (Fig.  5B) . We also examined the effects of cholesterol depletion on platelet activation induced by PMA, a potent protein kinase C (PKC) activator [16] . Although treatment of control platelets with 3 M PMA evoked platelet aggregation, PMA caused only a small increase in [Ca 2+ ] i in comparison with that induced by thrombin, ADP, or collagen. In cholesterol-depleted platelets, PMA-induced aggregation was significantly inhibited compared with that in control platelets (59.8  1.0% in control and 21.9  7.2% in MCD-treated platelets, P<0.05, n=3, in Fig. 5A) .
Effects of cholesterol enrichment on platelet activation: Finally, we examined the effects of cholesterol enrichment in platelets on aggregation and Ca 2+ mobilization induced by thrombin (Fig. 6) . Incubation of PRP with cholesterol/ MCD complexes significantly increased the cholesterol content in rabbit platelets in comparison with that in untreated platelets (0.30  0.03 mg in control and 0.41  0.04 mg in MCD-treated platelets, P<0.05, n=5, in Fig.  6A ). Platelet aggregation and Ca 2+ mobilization induced by 0.1 unit/ml thrombin were significantly augmented in the cholesterol-enriched platelets (aggregation; 44.6  5.8% in control and 61.2  2.2% in cholesterol-enriched platelets, Ca 2+ mobilization; 944.5  97.4 nM in control and 1799.0  88.1 nM in cholesterol-enriched platelets, P<0.05, n=5, in Fig. 6B and 6C) . A similar tendency was also observed at 0.01 unit/ml thrombin. These results suggest that the cholesterol content in platelets is a critical determinant in the regulation of platelet activation.
DISCUSSION
In the present study, we investigated the effects of in vitro modulation of cholesterol content in rabbit platelets on the platelet aggregation and Ca 2+ mobilization induced by platelet-aggregating agonists. We showed that platelet aggregation induced by physiological agonists such as thrombin, ADP, and collagen is inhibited by the treatment of platelets with MCD, which is commonly used to remove cholesterol from cell plasma membranes [36] . The inhibition of platelet aggregation by treatment with MCD is due to the decrease in the platelet cholesterol content, since the inhibition of thrombin-induced aggregation is significantly restored by cholesterol repletion by incubation of the MCD-treated platelets with cholesterol/MCD complexes. Furthermore, platelet shape change induced by thrombin or platelet aggregation induced by higher concentrations of thrombin (1 unit/ ml) was not affected by treatment of MCD, suggesting that the inhibitory effect of MCD is not due to the nonspecific toxic effect on platelets.
Consistent with a report regarding human platelets [6] , higher concentrations of thrombin (1 unit/ml) elicited platelet aggregation to a similar extent in both cholesteroldepleted and control platelets. This phenomenon might reflect the distinct sensitivity of thrombin receptors to cholesterol depletion, as in the case of ADP-induced human platelet activation, in which ADP receptor P2X 1 and P2Y 12 , but not P2Y 1 , exhibit dependencies on platelet cholesterol [20, 31] . In human platelets, thrombin activates a family of protease-activated receptors (PARs) such as PAR-1, -3, and -4, in which PAR-1 or PAR-4 mediates platelet responses at low or high concentrations of thrombin, respectively [10] . In rabbit platelets, expression of PAR-3 had been reported [11] . However, the thrombin-induced signaling pathways that promote rabbit platelet aggregation are essentially unknown. The expression pattern of the PARs and cholesterol dependencies of PARs must be elucidated in rabbit platelets.
A pivotal role of intracellular Ca 2+ mobilization in ADP secretion, TXA 2 generation, and platelet aggregation has been reported [22, 24, 27] . In agreement with the results of our aggregation experiment and previous reports regarding human platelets [6, 7, 30] To analyze the involvement of platelet cholesterol in the Ca 2+ -independent platelet activation pathway, we also examined the effects of MCD treatment on platelet activation induced by PMA, which directly activates intracellular PKC and results in ADP secretion and platelet aggregation without apparent Ca 2+ mobilization [4, 19] . It seems that PMA-induced aggregation is largely independent of Ca Finally, we demonstrated that the platelet aggregation and Ca 2+ mobilization induced by 0.1 unit/ml thrombin are significantly augmented in cholesterol-enriched rabbit platelets, in which cholesterol content was increased to 136% of control platelets. This result is in accordance with the observation that platelets from hypercholesterolemic humans and rabbits have increased cholesterol content (approximately 150% of control platelets) and hypersensitivity to platelet-aggregating agonists [3, 21, 25, 28] . Together, our results suggested that the cholesterol content in platelets is critical to the regulation of platelet activation both in vitro and in vivo.
It has been reported that endogenous agonists, TXA 2 and ADP, plays a crucial role in collagen-induced activation in human platelets, and in vitro cholesterol depletion reduces release of the endogenous agonists [4, 7, 27, 30] . We showed that, in rabbit platelets, cholesterol depletion not only decreased collagen-induced activation, but also suppressed platelet activation induced by ADP. It is likely that modulation of cholesterol content in rabbit platelets affect the release of endogenous agonists and/or activation mechanisms elicited by the released endogenous agonists. Further research focused on the roles of endogenous agonists is needed to clarify the precise mechanisms controlling the rabbit platelet activation by modulation of cholesterol contents.
In summary, we have shown that (1) cholesterol depletion in rabbit platelets by the treatment with MCD decreases the platelet aggregation and Ca 2+ mobilization induced by thrombin, (2) the Ca 2+ influx pathway is more sensitive to cholesterol depletion than Ca 2+ release from Ca 2+ stores, (3) cholesterol depletion also inhibits ADP-or collageninduced platelet activation, and (4) cholesterol enrichment augments thrombin-induced platelet activation. These findings suggest that cholesterol plays a critical role in regulating rabbit platelet activation, and provides fundamental information regarding hypercholesterolemia-mediated effects on cells in the rabbit model.
